Oregon Public Employees Retirement Fund Sells 1,152 Shares of Abbott Laboratories (NYSE:ABT)

Oregon Public Employees Retirement Fund cut its holdings in Abbott Laboratories (NYSE:ABTGet Rating) by 0.8% during the first quarter, HoldingsChannel reports. The firm owned 142,656 shares of the healthcare product maker’s stock after selling 1,152 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Abbott Laboratories were worth $16,885,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of ABT. Blue Bell Private Wealth Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $30,000. Delos Wealth Advisors LLC grew its position in Abbott Laboratories by 100.9% during the fourth quarter. Delos Wealth Advisors LLC now owns 231 shares of the healthcare product maker’s stock worth $33,000 after buying an additional 116 shares in the last quarter. Holloway Wealth Management LLC grew its position in Abbott Laboratories by 175.0% during the first quarter. Holloway Wealth Management LLC now owns 275 shares of the healthcare product maker’s stock worth $33,000 after buying an additional 175 shares in the last quarter. Retirement Group LLC grew its position in Abbott Laboratories by 1,125.0% during the fourth quarter. Retirement Group LLC now owns 245 shares of the healthcare product maker’s stock worth $34,000 after buying an additional 225 shares in the last quarter. Finally, Lumature Wealth Partners LLC grew its position in Abbott Laboratories by 65.4% during the fourth quarter. Lumature Wealth Partners LLC now owns 301 shares of the healthcare product maker’s stock worth $42,000 after buying an additional 119 shares in the last quarter. Institutional investors and hedge funds own 73.46% of the company’s stock.

Abbott Laboratories stock traded up $1.57 during trading hours on Friday, hitting $110.22. The company had a trading volume of 3,291,666 shares, compared to its average volume of 5,871,859. Abbott Laboratories has a one year low of $101.24 and a one year high of $142.60. The firm has a 50-day moving average of $111.39 and a 200 day moving average of $120.44. The firm has a market cap of $192.99 billion, a PE ratio of 25.57, a PEG ratio of 3.95 and a beta of 0.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.40.

Abbott Laboratories (NYSE:ABTGet Rating) last posted its quarterly earnings results on Wednesday, April 20th. The healthcare product maker reported $1.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.26. Abbott Laboratories had a net margin of 17.35% and a return on equity of 28.72%. The business had revenue of $11.90 billion for the quarter, compared to analyst estimates of $11 billion. During the same quarter last year, the business posted $1.32 EPS. The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. As a group, research analysts expect that Abbott Laboratories will post 4.84 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 1.71%. The ex-dividend date of this dividend is Thursday, July 14th. Abbott Laboratories’s payout ratio is currently 43.62%.

ABT has been the topic of a number of recent research reports. BTIG Research decreased their target price on Abbott Laboratories from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Royal Bank of Canada decreased their price objective on Abbott Laboratories from $146.00 to $143.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Wells Fargo & Company decreased their price objective on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating on the stock in a report on Friday, April 8th. Morgan Stanley decreased their price objective on Abbott Laboratories from $151.00 to $145.00 and set an “overweight” rating on the stock in a report on Tuesday, June 7th. Finally, StockNews.com assumed coverage on Abbott Laboratories in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $139.64.

In other news, Director Daniel J. Starks sold 50,000 shares of the company’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $113.22, for a total transaction of $5,661,000.00. Following the transaction, the director now owns 6,973,500 shares in the company, valued at $789,539,670. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Randel William Woodgrift sold 24,000 shares of the business’s stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $113.00, for a total transaction of $2,712,000.00. Following the sale, the senior vice president now directly owns 47,854 shares of the company’s stock, valued at $5,407,502. The disclosure for this sale can be found here. 0.52% of the stock is owned by company insiders.

Abbott Laboratories Company Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.